Imunon (IMNN) said Friday it received positive data showing improvement in overall and progression-free survival from a phase 2 study of IMNN-001, an investigational therapy for the treatment of advanced ovarian cancer.
The 112-patient study showed those treated with IMNN-001 plus chemotherapy had a median overall survival length of 46 months compared to 33 months for those treated with standard of care, the company said.
Imunon said it recently initiated the first two sites for a phase 3 study of the drug in newly diagnosed advanced ovarian cancer.
Shares of the company soared more than 145% in recent premarket activity.
Price: 1.00, Change: +0.58, Percent Change: +145.48
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。